Antitumor immunopreventive and immunotherapeutic effect in mice induced by hybrid vaccine of dendritic cells and hepatocarcinoma in vivo

Figure 1 Tumor tissue after 14 d subcutaneous incubation. HE, 3.3 × 10

Figure 2 Liver tissue of 14 d after hybrid vaccine injection by tail veil HE, 3. 3 × 20.

Figure 3 Lung tissue of 14 d after hybrid vaccine injection by tail veil HE, 3. 3 × 20.

Figure 4 CTL activity of different subgroup at different effec-tor/target ratio.

Figure 5 A: Comparison of latent time among different subgroups. B: Comparison of tumor weight among different subgroups. C: Comparison of tumor size among different subgroups. D: Comparison of survival period among different subgroups.

Figure 6 A: There isn’t obvious necrosis in tumor tissue of 14 d in pretective group P subgroup. HE, 3.3×20. B: There is dot like necrosis in tumor tissue of 14 d in pretective group H subgroup. HE, 3.3×20. C: There is sheet like necrosis in tumor tissue of 14 d in pretective group D subgroup. HE, 3.3×20. D: There is extensive necrosis in tumor tissue of 14 d in pretective group HD subgroup. HE, 3.3 × 20.

Figure 7 Comparison of tumor size on day 14 among different subgroups of therapeutic group.

Figure 8 A: There is dot or sheet like necrosis in tumor tissue of 14d in therapeutic group P subgroup. HE, 20×3.3. B: There is sheet like necrosis in tumor tissue of 14 d in therapeutic group D subgroup. HE, 20×3.3. C: There is sheet like necrosis in tumor tissue of 14 d in therapeutic group HD subgroup. HE, 20 × 3.3.